Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Chronic obstructive pulmonary disease

Potential role for benralizumab in COPD patients with eosinophilia

Micrograph of an eosinophil

Source: CNRI / Science Photo Library

Benralizumab’s treatment benefits were confined to patients with raised eosinophils

Eosinophilic airway inflammation is present in 10% to 20% of patients with chronic obstructive pulmonary disease (COPD) and may be associated with more severe disease.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, is known to deplete blood and sputum eosinophils and may also have clinical benefits in COPD. According to results of a Phase IIa study published in The Lancet Respiratory Medicine (online, 8 September 2014)[1], benralizumab therapy led to a numerical, albeit not statistically significant, improvement in COPD exacerbations and lung function compared with placebo.

These treatment benefits were confined to the subgroup of patients with raised eosinophils at baseline, leading Christopher Brightling, from the University of Leicester, and co-authors to call for further investigation of benralizumab in COPD patients with eosinophilia.

 

  • The authors’ conclusion that benralizumab warrants further investigation for patients with COPD and eosinophilia was based on non-significant findings from a prespecified subgroup analysis. The headline of this story was update on 11 September 2014 to better reflect this. The study did not meet its primary endpoint of improvement in acute exacerbations.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066395

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.